NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma
NCT03215524: Phase 2 - Daratumumab, Low-Dose Dex and Cyclophosphamide +/- Pomalidomide (DCDP)
NCT03188172: Phase 2 - MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)
NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
NCT02951819: Phase 2 - Evaluate Dara-CyBorD in Previously Untreated and RRMM - LYRA